Article Details

Cadent Pulls In $40M for Phase 2 Tests of Movement Disorder Drug

Retrieved on: 2018-11-14 18:52:30

Tags for this article:

Click the tags to see associated articles and topics

Cadent Pulls In $40M for Phase 2 Tests of Movement Disorder Drug. View article details on hiswai:

Excerpt

<div>Venture capital firm <b>Atlas Venture</b> acquired the drug and gave Saniona equity in a new startup, Ataxion, that it formed in 2013 to develop the ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo